In this editorial Yu Shrike Zhang (Harvard Medical School; MA, USA), a previous finalist of the Bioanalysis Rising Star Award, discusses his research and hopes for the future. He details the emergence of organ-on-a-chip systems and how these platforms reproduce tissue functions outside the human body.
Browsing: Expert opinion
Considerations for developing and validating an LC–MS biomarker assay using the surrogate peptide approach
In this editorial, Timothy Sikorski (GSK; PA, USA), discusses particular considerations for developing and validating LC–MS biomarker assays using the surrogate peptide approach.
In this editorial, Robert MacNeill (Envigo) dicusses the case for the surrogate analyte approach for biomarker validation.
Find out more about ensuring the validity of biomarker measurements in this Editorial from Liam Heaney (University of Loughborough, UK).
Developing bioanalytical LC–MS/MS methods for biotherapeutics and biomarkers: an interview with William Mylott
In this expert interview, William Mylott discusses developing bioanalytical LC–MS/MS methods for biotherapeutics and biomarkers.
In this interview, Lawrence Goodwin (KCAS, KS, USA) explains his passion for tandem technology, the portfolio of services that KCAS offers and the advantages and disadvantages of their key technologies chromatography and mass spectrometry.
Read time: 3:45 mins
Find out more about the immunogenicity of antibody–drug conjugates (ADCs) in this column from Corinna Fiorotti, Business Development Director at BioAgilytix (NC, USA).
Read time: 3 mins
In this installment, Robert discusses how to get to grips with metabolites; the ways in which metabolites may affect the performance and reliability of an assay, and what could be done to overcome them.
Read time: 5:30 mins
In this interview, Arno Kromminga discusses the benefits and challenges associated with current methods, and what he believes the future holds for immunogencity.
Read time: 3:30 mins
The value of lipid biomarkers for precision medicine is growing in recognition, resulting in an increased research focus on translational lipidomic workflows. Underpinning advances in this field are developments in mass spectrometry (MS) and liquid chromatography (LC). In this editorial, David Peake (Thermo Fisher Scientific) considers the analytical challenges associated with translational lipid biomarker development, and how the latest LC–MS technologies and lipidomics workflows are overcoming them.